(-)-Ropivacaine-d7 (hydrochloride)
(Synonyms: (S)-Ropivacaine-d7) 目录号 : GC46248
An internal standard for the quantification of (–)-ropivacaine
Cas No.:1217667-10-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
(-)-Ropivacaine-d7 is intended for use as an internal standard for the quantification of (-)-ropivacaine by GC- or LC-MS. (-)-Ropivacaine is a potent and reversible blocker of sodium channels in nerve fibers.1 In vivo, (-)-ropivacaine induces complete impairment of proprioception, motor function, and nociception in the hindleg of rats when 100 μL of an 8 mM solution is injected percutaneously into the sciatic nerve.2 (-)-Ropivacaine depresses myocardial contractile force in isolated rat hearts less potently than (±)-ropivacaine, as well as (-)- and (±)-bupivacaine .3 Formulations containing (-)-ropivacaine have been used as local anesthetics during surgery and childbirth.
1.Hansen, T.G.Ropivacaine: A pharmacological reviewExp. Rev. Neurother.4(5)781-791(2004) 2.Sinnott, C.J., and Strichartz, G.R.Levobupivacaine versus ropivacaine for sciatic nerve block in the ratReg. Anesth. Pain Med.28(4)294-303(2003) 3.Pinotti, M.F., Hepner, A., Campos, D.H., et al.Myocardial contractility impairment with racemic bupivacaine, non-racemic bupivacaine and ropivacaine. A comparative studyActa Cir. Bras.30(7)484-490(2015)
| Cas No. | 1217667-10-1 | SDF | |
| 别名 | (S)-Ropivacaine-d7 | ||
| Canonical SMILES | CC1=CC=CC(C)=C1NC([C@H]2N(C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])CCCC2)=O.Cl | ||
| 分子式 | C17H19D7N2O.HCl | 分子量 | 317.9 |
| 溶解度 | Methanol: soluble,Water: soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1456 mL | 15.7282 mL | 31.4564 mL |
| 5 mM | 0.6291 mL | 3.1456 mL | 6.2913 mL |
| 10 mM | 0.3146 mL | 1.5728 mL | 3.1456 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet